Market Closed -
Nasdaq Copenhagen
10:01:50 2024-05-08 am EDT
|
5-day change
|
1st Jan Change
|
1,010
DKK
|
-7.76%
|
|
+2.20%
|
-24.06%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
864.4
|
1,447
|
2,328
|
599.8
|
31.07
|
46.96
|
Enterprise Value (EV)
1 |
469.6
|
1,400
|
1,672
|
537.5
|
-11.39
|
28.75
|
P/E ratio
|
-3.77
x
|
-4.29
x
|
-3.01
x
|
-0.96
x
|
1.19
x
|
-1.8
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
16,571,611
x
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
14,850,643
x
|
-
|
-
|
EV / EBITDA
|
-2.04
x
|
-4.19
x
|
-2.76
x
|
-0.94
x
|
0.41
x
|
-2.38
x
|
EV / FCF
|
-3.08
x
|
-6.68
x
|
-5.33
x
|
-1.44
x
|
0.18
x
|
-16
x
|
FCF Yield
|
-32.4%
|
-15%
|
-18.8%
|
-69.5%
|
563%
|
-6.26%
|
Price to Book
|
2.23
x
|
27.3
x
|
3.75
x
|
64.2
x
|
0.75
x
|
3.3
x
|
Nbr of stocks (in thousands)
|
19.9
|
20
|
34.7
|
35
|
35.3
|
35.3
|
Reference price
2 |
43,350
|
72,400
|
67,100
|
17,160
|
880.0
|
1,330
|
Announcement Date
|
3/1/19
|
2/28/20
|
3/2/21
|
6/7/22
|
4/25/23
|
3/27/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
-
|
-
|
36.19
|
-
|
-
|
EBITDA
1 |
-230.3
|
-334.2
|
-606.4
|
-571.9
|
-28.03
|
-12.1
|
EBIT
1 |
-231.7
|
-336
|
-608.5
|
-586.7
|
-41.24
|
-12.88
|
Operating Margin
|
-
|
-
|
-
|
-1,621.04%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-235.1
|
-343
|
-635.2
|
-631.5
|
-41.05
|
-26.05
|
Net income
1 |
-229.6
|
-337.5
|
-633.2
|
-626.5
|
26.07
|
-26.05
|
Net margin
|
-
|
-
|
-
|
-1,731.11%
|
-
|
-
|
EPS
2 |
-11,500
|
-16,873
|
-22,324
|
-17,940
|
739.2
|
-737.7
|
Free Cash Flow
1 |
-152.4
|
-209.6
|
-313.7
|
-373.4
|
-64.09
|
-1.8
|
FCF margin
|
-
|
-
|
-
|
-1,031.77%
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/1/19
|
2/28/20
|
3/2/21
|
6/7/22
|
4/25/23
|
3/27/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
395
|
46.5
|
656
|
62.3
|
42.5
|
18.2
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-152
|
-210
|
-314
|
-373
|
-64.1
|
-1.8
|
ROE (net income / shareholders' equity)
|
-45.7%
|
-153%
|
-188%
|
-199%
|
-150%
|
-94.3%
|
ROA (Net income/ Total Assets)
|
-26.2%
|
-67.5%
|
-75.8%
|
-73.7%
|
-22.3%
|
-21.2%
|
Assets
1 |
875.5
|
500
|
835.2
|
850.7
|
-117
|
123.1
|
Book Value Per Share
2 |
19,471
|
2,650
|
17,884
|
267.0
|
1,180
|
403.0
|
Cash Flow per Share
2 |
19,795
|
6,184
|
20,950
|
2,926
|
1,203
|
319.0
|
Capex
1 |
0.74
|
2.78
|
2.37
|
0.09
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
0.25%
|
-
|
-
|
Announcement Date
|
3/1/19
|
2/28/20
|
3/2/21
|
6/7/22
|
4/25/23
|
3/27/24
|
|
1st Jan change
|
Capi.
|
---|
| -24.06% | 5.15M | | +3.91% | 109B | | +10.87% | 105B | | +1.28% | 22.25B | | -13.14% | 22.09B | | -7.05% | 18.68B | | -38.36% | 17.58B | | -10.66% | 16.85B | | +3.75% | 13.76B | | +36.70% | 12.46B |
Bio Therapeutic Drugs
|